



## Multiple Sclerosis



**Factory:** Alinasab Industrial Town, Serum Darou St., Opp. Agricultural Training Center, 19th Km Tehran Road, Tabriz, Iran. | Zip code: 5169191590  
**Phone:** +98 41 363094016 | **Fax:** +98 41 36309400  
**Office:** No. 23, Darou paksh Ave, 18th km Tehran-karaj Makhsoos Road, Tehran- Iran.  
**Zip code:** 1397116396 | **Phone:** +98 21 44993193 **Fax:** +98 41 44994315  
**Web site:** [www.zahraui.com](http://www.zahraui.com) | **Email:** [Office@zahravipharma.com](mailto:Office@zahravipharma.com)



# Famzeera® E.R.

## Fampridine 10 mg Extended-Release Tablets

Enhancing Mobility, Elevating Life Quality

eRx Code: 66273




**ZAHRAUI**  
PHARMACEUTICAL CO.  
Tabriz - IRAN



## Clinical Evidence in Multiple Sclerosis (MS):

Fampridine E.R. has been shown to improve walking ability, balance, physical functioning, quality of life, and cognition in patients with multiple sclerosis. Integrated analyses of the MOBILE and ENHANCE trials (n = 765) demonstrated that, over 24 weeks, a higher proportion of patients treated with Fampridine E.R. achieved clinically meaningful improvement:

- Walking Ability (MSWS-12): 44.3% of Fampridine-treated patients achieved clinically meaningful improvement versus 33.0% with placebo (p < 0.001).
- Dynamic and Static Balance: Improvements observed in Timed Up and Go (TUG) and Berg Balance Scale (BBS) scores.
- Physical Impact of MS: Patients reported reduced physical impact, measured by MSIS-29 PHYS.
- Quality of Life: Enhanced scores in EQ-5D utility index and Visual Analogue Scale (VAS).
- Consistency: Benefits were maintained across patient subgroups.



## Figure - Walking and Mobility Outcomes

Over 24 weeks, a higher proportion of patients with multiple sclerosis (PwMS) treated with Fampridine achieved clinically meaningful improvements in walking ability, measured by the 12-item Multiple Sclerosis Walking Scale (MSWS-12, ≥ 8-point improvement), and in mobility, measured by the Timed Up and Go (TUG) test, ≥15% improvement in speed, compared with placebo. These results demonstrate enhanced functional performance and mobility in MS patients.

## Cognitive Function:

A meta-analysis of 15 studies (2013–2021) confirmed that Fampridine also improves cognitive performance in MS patients. Treated patients demonstrated moderate gains in information processing speed and attention (SDMT, SMD = 0.45, 95% CI: 0.06–0.84, p < 0.001) and smaller but significant improvements in working memory and mental calculation (PASAT, SMD = 0.25, 95% CI: 0.13–0.37, p < 0.001). These findings indicate that Fampridine supports both mobility and cognitive function in MS.

## Safety Profile:

Fampridine was generally well tolerated, with a safety profile similar to placebo. Adverse events were mostly mild to moderate and occurred slightly more often in patients who responded to treatment in walking ability (MSWS-12 responders, 22%) compared with non-responders (15%) or placebo (14%).



## Famzeera® E.R. – Empowering MS Patients Every Step of the Way

- Enhances Walking & Mobility
- Improves Balance
- Boosts Physical Function & Quality of Life
- Supports Cognitive Performance
- Promotes Independence

• Hupperts R, Gasperini C, Lycke J, Ziemssen T, Feys P, Xiao S, Acosta C, Koster T, Hobart J. Efficacy of prolonged-release fampridine versus placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE. *Ther Adv Neurol Disord*. 2022 May 18; 15:17562864221090398. doi: 10.1177/17562864221090398. PMID: 35601756; PMCID: PMC9121513.

• Naser Moghadasi A, Ebrahimi N, Bagherieh S, Mohammadi A, Sahraian MA, Ghajarzadeh M. Effect of Fampridine on cognition in patients with multiple sclerosis (MS): a systematic review and meta-analysis. *Caspian J Intern Med*. 2025 May 15;16(3):384-392. doi: 10.22088/cjim.16.3.384. PMID: 40786588; PMCID: PMC12329368.